Michael Reusch

Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan

Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi et al. · Journal of the American Society of Nephrology · 2020 · 196 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases

Matthias Augustin, Marc Alexander Radtke, I. Zschocke et al. · Archives of Dermatological Research · 2009 · 189 citations

Pharmacy, Dermatology, Cost-utility Analysis +16

Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)

Jonathan Barratt, Branislav Andrić, Avtandil Tataradze et al. · Nephrology Dialysis Transplantation · 2021 · 143 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)

Evgeny Shutov, Władysław Sułowicz, Ciro Esposito et al. · Nephrology Dialysis Transplantation · 2021 · 118 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data

Ines Schaefer, Matthias Augustin, C. Spehr et al. · Journal of the European Academy of Dermatology and Venereology · 2013 · 114 citations

Medicine, Dermatology, Ophthalmology +9